...
首页> 外文期刊>European journal of cancer care >Prediction of outcome in cancer patients with febrile neutropenia: comparison of the Multinational Association of Supportive Care in Cancer risk-index score with procalcitonin, C-reactive protein, serum amyloid A, and interleukins-1beta, -6, -8 and -
【24h】

Prediction of outcome in cancer patients with febrile neutropenia: comparison of the Multinational Association of Supportive Care in Cancer risk-index score with procalcitonin, C-reactive protein, serum amyloid A, and interleukins-1beta, -6, -8 and -

机译:发热性中性粒细胞减少症癌症患者预后的预测:多国癌症支持治疗协会风险指数评分与降钙素,C反应蛋白,血清淀粉样蛋白A和白介素-1β,-6,-8和-

获取原文
获取原文并翻译 | 示例
           

摘要

The primary objective of the study was to compare the predictive potential of procalcitonin (PCT), C-reactive protein (CRP), serum amyloid A (SAA), and interleukin (IL)-1beta, IL-6, IL-8, and IL-10, with that of the Multinational Association of Supportive Care in Cancer (MASCC) risk-index score in cancer patients on presentation with chemotherapy-induced febrile neutropenia (FN). Seventy-eight consecutive FN episodes in 63 patients were included, and MASCC scores, as well as concentrations of CRP, SAA, PCT, and IL-1beta, IL-6, IL-8 and IL-10, and haematological parameters were determined on presentation, 72 h later and at outcome. Multivariate analysis of data revealed the MASCC score, but none of the laboratory parameters, to be an accurate, independent variable (P < 0.0001) for prediction of resolution with or without complications and death. Of the various laboratory parameters, PCT had the strongest association with the MASCC score (r = -0.51; P < 0.0001). In cancer patients who present with FN, the MASCC risk-index score is a useful predictor of outcome, while measurement of PCT, CRP, SAA, or IL-1beta, IL-6, IL-8 and IL-10, is of limited value.
机译:这项研究的主要目的是比较降钙素(PCT),C反应蛋白(CRP),血清淀粉样蛋白A(SAA)和白介素(IL)-1beta,IL-6,IL-8和IL-10与多国癌症支持治疗协会(MASCC)的癌症患者因化疗引起的发热性中性粒细胞减少症(FN)的风险指数评分相比较。纳入63例患者中的78例连续FN发作,并通过以下方法确定MASCC评分以及CRP,SAA,PCT和IL-1beta,IL-6,IL-8和IL-10的浓度以及血液学参数演示文稿,在72小时后并取得结果。数据的多变量分析显示,MASCC评分是一项准确,独立的变量(P <0.0001),可用于预测有无并发症和死亡的分辨率,但没有任何实验室参数。在各种实验室参数中,PCT与MASCC评分之间的关​​联最强(r = -0.51; P <0.0001)。在患有FN的癌症患者中,MASCC风险指数评分是预测结局的有用指标,而PCT,CRP,SAA或IL-1beta,IL-6,IL-8和IL-10的测量是有限的值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号